ARS Pharmaceuticals, Inc. (SPRY) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
SPRY currently has 99.3M outstanding shares. with significant dilution risk as 64.8M authorized shares could dilute existing holders by 65.3%. The company has minimally diluted shareholders by 2.87% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 15, 2026 |
10-Q filing | 99.3M shares outstanding |
99M | 65M |
| Mar 09, 2026 |
10-K filing | 98.6M shares outstanding |
99M | 65M |
| Nov 10, 2025 |
10-Q filing | 98.8M shares outstanding |
99M | 65M |
| Aug 13, 2025 |
10-Q filing | 98.4M shares outstanding |
98M | 65M |
| May 14, 2025 |
10-Q filing | 98.1M shares outstanding |
98M | 65M |
| Mar 20, 2025 |
10-K filing | 96.9M shares outstanding |
97M | 65M |
| Nov 13, 2024 |
10-Q filing | 97.0M shares outstanding |
97M | 65M |
| Aug 06, 2024 |
10-Q filing | 96.8M shares outstanding |
97M | 65M |
| May 09, 2024 |
10-Q filing | 96.5M shares outstanding |
96M | 65M |
| Mar 21, 2024 |
10-K filing | 95.2M shares outstanding |
95M | 65M |
| Nov 09, 2023 |
10-Q filing | 95.6M shares outstanding |
96M | 65M |
| Aug 10, 2023 |
10-Q filing | 94.9M shares outstanding |
95M | 65M |
| May 15, 2023 |
10-Q filing | 94.2M shares outstanding |
94M | 65M |
| Apr 20, 2023 |
S-3 filing: This S-3 filing relates to the proposed resale of 64,779,432 shares of common stock by selling stockholders. |
94M | 65M |
| Mar 23, 2023 |
10-K filing | 94.4M shares outstanding |
94M | 34K |
| Nov 02, 2022 |
10-Q filing | 35.5M shares outstanding |
35M | 34K |
| Aug 11, 2022 |
10-Q filing | 35.5M shares outstanding |
35M | 34K |
| May 12, 2022 |
10-Q filing | 35.1M shares outstanding |
35M | 34K |
| Mar 31, 2022 |
10-K filing | 35.1M shares outstanding |
35M | 34K |
| Jan 03, 2022 |
S-3 filing: The filing is for a shelf offering of common stock, preferred stock, and debt securities with a total proposed amount of $250,000,000. |
35M | 34K |
| Nov 10, 2021 |
10-Q filing | 35.1M shares outstanding |
35M | 34K |
| Aug 12, 2021 |
10-Q filing | 35.0M shares outstanding |
35M | 34K |
| May 13, 2021 |
10-Q filing | 34.9M shares outstanding |
35M | 34K |
| Dec 03, 2020 |
S-1/A filing: An S-1/A filing indicates a company intends to offer 10,000,000 shares of common stock, with 808,611 shares of common stock outstanding as of September 30, 2020, excluding redeemable convertible preferred stock. The filing also mentions the potential issuance of shares through stock options and future equity or convertible debt securities, which may cause dilution. |
810K | 34K |
| Nov 30, 2020 |
S-1/A filing: The document is an S-1/A filing related to Silverback Therapeutics, Inc. and includes details about the company's 2020 Equity Incentive Plan, outstanding stock options, and potential dilution from future equity issuances. |
22M | 34K |
| Nov 10, 2020 |
S-1 filing: This is an S-1 filing for a company offering common stock through stock options granted under their 2016 Equity Incentive Plan and through warrants issued to lenders, while also reserving shares for future issuance under the 2020 Plan and ESPP. |
80M | 34K |